You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

CLINICAL TRIALS PROFILE FOR NISOLDIPINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for NISOLDIPINE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00311870 ↗ Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy Completed Bayer Phase 4 1993-03-01 The aim of the study was to compare the renoprotective effect of a long acting calcium antagonist (nisoldipine) with an angiotensin converting enzyme inhibitor (lisinopril)in type 1 diabetic patients with diabetic kidney disease. In total, 51 patients were randomised to treatment with one of these drugs for 4 years. Changes in kidney function, blood pressure and urinary excretion of albumin were measured every 6 months
NCT00311870 ↗ Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy Completed Steno Diabetes Center Phase 4 1993-03-01 The aim of the study was to compare the renoprotective effect of a long acting calcium antagonist (nisoldipine) with an angiotensin converting enzyme inhibitor (lisinopril)in type 1 diabetic patients with diabetic kidney disease. In total, 51 patients were randomised to treatment with one of these drugs for 4 years. Changes in kidney function, blood pressure and urinary excretion of albumin were measured every 6 months
NCT00311870 ↗ Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy Completed Steno Diabetes Center Copenhagen Phase 4 1993-03-01 The aim of the study was to compare the renoprotective effect of a long acting calcium antagonist (nisoldipine) with an angiotensin converting enzyme inhibitor (lisinopril)in type 1 diabetic patients with diabetic kidney disease. In total, 51 patients were randomised to treatment with one of these drugs for 4 years. Changes in kidney function, blood pressure and urinary excretion of albumin were measured every 6 months
NCT00730197 ↗ Fasting Bioequivalence Study of Nisoldipine Extended-Release Tablets 40 mg Completed Mylan Pharmaceuticals Phase 1 2007-02-01 The objective of this study was to investigate the bioequivalence of nisoldipine extended-release 40 mg tablets (by Mylan Pharmaceuticals Inc.) with Sular® Extended-Release 40 mg tablet (manufactured for First Horizon) following a single, oral 40 mg (1 × 40 mg tablet) dose administration in healthy adult subjects under fasting conditions.
NCT00979537 ↗ Single-Dose Fed Bioequivalence Study of Nisoldipine Extended-Release Tablets (40 mg; Mylan) and Sular® Extended-Release Tablets (40 mg; First Horizon) in Healthy Volunteers Completed Mylan Pharmaceuticals Phase 1 2007-03-01 The objective of this study was to investigate the bioequivalence of nisoldipine extended-release 40 mg tablets (by Mylan Pharmaceuticals Inc.) with Sular® Extended-Release 40 mg tablet (manufactured for First Horizon) following a single, oral 40 mg (1 × 40 mg tablet) dose administration in healthy adult subjects under fed conditions.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for NISOLDIPINE

Condition Name

Condition Name for NISOLDIPINE
Intervention Trials
Healthy 3
Hypertension 2
Diabetic Nephropathy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for NISOLDIPINE
Intervention Trials
Hypertension 2
Diabetic Nephropathies 1
Kidney Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for NISOLDIPINE

Trials by Country

Trials by Country for NISOLDIPINE
Location Trials
United States 3
Bulgaria 1
Hungary 1
Denmark 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for NISOLDIPINE
Location Trials
North Dakota 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for NISOLDIPINE

Clinical Trial Phase

Clinical Trial Phase for NISOLDIPINE
Clinical Trial Phase Trials
Phase 4 3
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for NISOLDIPINE
Clinical Trial Phase Trials
Completed 4
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for NISOLDIPINE

Sponsor Name

Sponsor Name for NISOLDIPINE
Sponsor Trials
Mylan Pharmaceuticals 3
Menarini International Operations Luxembourg SA 2
Bayer 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for NISOLDIPINE
Sponsor Trials
Industry 6
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.